Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Spero Therapeutics (Nasdaq: SPRO) said it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025 after the market close. The company noted it does not intend to host a conference call.
Spero is a clinical-stage biopharmaceutical company focused on novel treatments for rare diseases and multi-drug resistant bacterial infections.
Spero Therapeutics (Nasdaq: SPRO) ha detto che riferirà i risultati finanziari del terzo trimestre 2025 e fornirà un aggiornamento sull'attività il giovedì 13 novembre 2025, dopo la chiusura del mercato. L'azienda ha osservato che non intende tenere una conference call.
Spero è una società biofarmaceutica in fase clinica focalizzata su trattamenti innovativi per malattie rare e infezioni batteriche multiresistenti.
Spero Therapeutics (Nasdaq: SPRO) anunció que reportará sus resultados financieros del tercer trimestre de 2025 y proporcionará una actualización comercial el jueves 13 de noviembre de 2025 después del cierre del mercado. La compañía señaló que no tiene la intención de celebrar una llamada de conferencia.
Spero es una empresa biofarmacéutica en etapa clínica enfocada en tratamientos innovadores para enfermedades raras e infecciones bacterianas multirresistentes.
Spero Therapeutics (Nasdaq: SPRO)는 2025년 3분기 재무실적을 발표하고 시장 마감 후 2025년 11월 13일 목요일에 비즈니스 업데이트를 제공할 것이라고 밝혔다. 회사는 컨퍼런스 콜을 개최하지 않을 예정이라고 언급했다.
Spero는 희귀 질환 및 다제 내성 박테리아 감염에 대한 새로운 치료를 중심으로 임상단계 생물의약 회사이다.
Spero Therapeutics (Nasdaq : SPRO) a déclaré qu'il dévoilera ses résultats financiers du troisième trimestre 2025 et fournira une mise à jour commerciale le jeudi 13 novembre 2025 après la clôture du marché. La société a précisé qu'elle n'organisera pas de conférence téléphonique.
Spero est une société biopharmaceutique en phase clinique axée sur des traitements innovants pour les maladies rares et les infections bactériennes multirésistantes.
Spero Therapeutics (Nasdaq: SPRO) sagte, dass es seine Finanzergebnisse des dritten Quartals 2025 berichten und am Donnerstag, dem 13. November 2025 nach Börsenschluss ein Update zum Geschäft geben wird. Das Unternehmen merkte an, dass es keine Telefonkonferenz ausrichten wird.
Spero ist ein klinisch-phasenbiotechnologisches Unternehmen, das sich auf neue Behandlungen für seltene Krankheiten und multiresistente bakterielle Infektionen konzentriert.
Spero Therapeutics (Nasdaq: SPRO) قالت إنها ستعلن عن النتائج المالية للربع الثالث من 2025 وستقدم تحديثاً عن الأعمال في الخميس 13 نوفمبر 2025 بعد إغلاق السوق. وأشارت الشركة إلى أنها لا تعتزم عقد مؤتمر هاتفي.
Spero هي شركة أدوية حيوية في المرحلة السريرية تركز على علاجات مبتكرة للأمراض النادرة والعدوى البكتيرية متعددة المقاومة.
- None.
- None.
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com
Spero Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@sperotherapeutics.com
Spero Media Inquiries:
media@sperotherapeutics.com
FAQ
When will Spero Therapeutics (SPRO) report its Q3 2025 results?
Will Spero Therapeutics (SPRO) host a conference call for the Q3 2025 results?
How will Spero Therapeutics (SPRO) provide the November 13, 2025 business update?
What is Spero Therapeutics (SPRO) known for as of November 4, 2025?
Will investors be able to ask questions during Spero's Q3 2025 report on November 13, 2025?
